Skip to main content
Premium Trial:

Request an Annual Quote

DoubleTwist to Incorporate Genomatix s Gene Promoter Data in Database

NEW YORK, Jan 23 – DoubleTwist has signed an agreement with Genomatix Software, in which Genomatix will integrate its gene promoter software into Doubletwist’s genome database and Doubletwist will exclusively distribute the combined product, the companies announced Tuesday.

The first-of-a-kind deal allows DoubleTwist to license Genomatix’s Promoter Resource Database for sale alone or with DoubleTwist’s Prophecy genome database and analysis package. Under the agreement, Genomatix will also have access to DoubleTwist’s annotated genome database.

While Genomatix would not disclose the size of the deal, spokesman Klaus May said the company also discussed sharing its data with Celera and Incyte, who have also developed annotated genome databases. But ultimately, Genomatix went with DoubleTwist, he said, because of its scientists, its “convincing concept,” and because it has “one of the best sales forces around.”

DoubleTwist’s human genome is available online or can be purchased for an internal network along with other data mining and viewing software.

Genomatix's promoter database, which it completed at the end of July, covers some 40,000 promoters across the genome. “We do not find every promoter--perhaps every second—but every one we find has a 90 percent probability of actually being a gene,” said May.

Promoters, or sites upstream from DNA coding sequences, show promise as more accurate markers of where genes begin and why they are expressed, said May. “When you use a promoter as a starting point for your algorithm,” May said, “your specificity [for identifying genes] goes up by orders of magnitude.”

DoubleTwist said it went with Genomatix because it is the only company to have precisely isolated human promoter sequences, according to DoubleTwist CEO John Couch. " By combining their promoter database with our Annotated Human Genome Database, we expect to further enhance scientists' ability to better understand the genome,” Couch said in a statement.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.